FDA Retracts Refuse-to-File Letter Sent to Alkermes in March

Drug Industry Daily
A A
The FDA rescinded a refuse-to-file letter it issued to Alkermes in March for the company’s experimental treatment for depressive disorder, the company announced Monday.

To View This Article:

Login

Subscribe To Drug Industry Daily